Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Vascular disorders – page 62

  • 838 clinical trials
  • 353 recruiting
  • 378 conditions
  • 28 countries

Conditions in this area

378 conditions with trials, the busiest first

Ischaemic stroke52Migraine48Systemic scleroderma39Pulmonary arterial hypertension38Coronary artery disease37Arteriosclerosis32Acute myocardial infarction30Hypertension27Pulmonary hypertension23Acute coronary syndrome21Giant cell arteritis18Peripheral arterial occlusive disease17Septic shock17Cardiovascular disorder16Paroxysmal nocturnal haemoglobinuria16Subarachnoid haemorrhage16Acute respiratory distress syndrome15Atrial fibrillation15Cerebrovascular accident14Pulmonary embolism14Anti-neutrophil cytoplasmic antibody positive vasculitis13Diabetic foot13Embolism13Myocardial infarction13+354

Clinical trials in Vascular disorders

838 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

838 clinical trials

Coronary artery disease

Not recruiting

Study of RBD4059 and acetylsalicylic acid in patients with stable coronary artery disease: evaluation of safety and drug behavior in the body

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Ribocure Pharmaceuticals AB

Thrombotic microangiopathy

Not recruiting

Study of Pegcetacoplan (APL-2) in Patients with Transplant-associated Thrombotic Microangiopathy After Stem Cell Transplantation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Macular telangiectasia

Not recruiting

Study Comparing Aflibercept and Placebo for Patients with Macular Telangiectasia Type 1

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Haemorrhoids

Not recruiting

Study on Pain Relief for Hemorrhoids Using Ropivacaine and Ropivacaine Hydrochloride in Patients Undergoing Radiofrequency Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ropivacaine
  • Sponsor:Centre Hospitalier Departemental Vendee

Coronary artery disease

Not recruiting

Gene Therapy Study for Severe Coronary Artery Disease Using AdsVEGF-D Delta N Delta C in Patients with Refractory Angina

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Adenovirus Vector Serotype 5 Containing The Vascular Endothelial Growth Factor D Isoform (Preprocessed Short Form)
  • Sponsor:Pohjois-Savon hyvinvointialue

Subarachnoid haemorrhage

Not recruiting

Study on the Effects of Dexamethasone in Patients with Aneurysmal Subarachnoid Hemorrhage

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone Sodium Phosphate
  • Sponsor:Rheinische Friedrich-Wilhelms-Universitaet Bonn

Embolism

Not recruiting

Study on REGN7508 for Preventing Blood Clots in Adults After Knee Replacement Surgery

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Enoxaparin Sodium
  • Sponsor:Regeneron Pharmaceuticals Inc.

Cardiac ventricular thrombosis+1

Not recruiting

Study on Dabigatran and Phenprocoumon for Treating Left Ventricular Thrombosis After Heart Attack in Patients with STEMI

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Medical University Of Graz

Sepsis+1

Not recruiting

Study on Noradrenaline and Terlipressin for Treating Septic Shock in Patients

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Terlipressin Acetate
  • Sponsor:Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study on Long-Term Safety and Tolerability of Iptacopan for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Hypertension

Not recruiting

Study on the Effects of Amlodipine and Irbesartan in Patients with High Blood Pressure

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Amlodipine
  • Sponsor:Win Medica Pharmaceutical S.A.

Acute myocardial infarction

Not recruiting

Study on Ticagrelor for Patients with Heart Attack After Coronary Stenting

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Ticagrelor
  • Sponsor:Vaestra Goetalandsregionen

Substances studied in this area

The therapies tested most often in Vascular disorders trials.

Acetylsalicylic Acid59 clinical trialsSodium Chloride55 clinical trialsClopidogrel33 clinical trialsApixaban28 clinical trialsTicagrelor28 clinical trialsRivaroxaban21 clinical trialsAtorvastatin17 clinical trialsPrasugrel17 clinical trialsRituximab16 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.